In some human studies, irisin has been positively associated with risk of metabolic syndrome, cardiometabolic disturbances, and cardiovascular disease, suggesting either an increased secretion in adipocytes or muscle cells and/or irisin resistance in these subjects with an increased compensatory secretion (76). This evidence concerns the gene FNDC5 and metabolic syndrome.